Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Objective To evaluate the efficacy and safety of combination of candesartan cilexetial and hydrochlorothiazide (16.0 mg/12.5 mg) in patients with mild and moderate hypertension.Methods A 8 weeks,multicenter, double-blind,randomized,parallel-group study was carried out.After 2 weeks wash-out phase,treatment started with once-daily 8 mg candesartan cilexetil in the 392 patients for 4 weeks(phase 1 study);if target sitting diastolic BP(SeDBP90 mm Hg) was not achieved,the dose were titrated to candesartan 16 mg alone or candesartan 16.0 mg/hydrochlorothiazide 12.5 mg pill once daily for 8 weeks(phase 2 study).Results The reduction of BP were 10.2±10.6/6.5±5.7 mm Hg after 4 weeks treatment of 8 mg candesartan cilexetial alone(n=353),only 54 (15.3%) patients achieved the target DBP.During the consequential 8 weeks treatment,the antihypertensive effect of combined treatment(n=134) was much greater than that by candesartan alone(n=142)(11.1±11.2/10.7±6.6 mm Hg vs 7.8±11.1/7.8±6.3 mm Hg,P0.01).The number of patients who achieved the target DBP were 73/142(51.4%) by monotherapy vs 107/134(79.9%) by combined treatment(P0.01).Patients were well tolerated in both groups with no difference in drug-related adverse events.Conclusion The combined candesartan cilexetiain and hydrochlorothiazide treatment is more effective and well tolerated in patients with mild and molderate hypertension than that by candesartan monotherapy.